|
EP3708162A1
|
|
Macrocycles with antioxidant and neuroprotective activities
|
|
EP3656762A1
|
|
Compounds for the treatment of nf-kb-related diseases or disorders
|
|
US2016152566A1
|
|
Tricyclic pyrrole compounds, their preparation and use in medicaments
|
|
WO2012062906A1
|
|
Peptides as bioactive compounds
|
|
WO2012010606A1
|
|
Hexacyclic polyketides as kinase inhibitors
|
|
EP2167073A1
|
|
Terpenes with antifungal activity against malassezia yeasts
|
|
GB0618440D0
|
|
Lipopeptides as antitumoral compounds
|
|
GB0524165D0
|
|
Antitumoral compounds
|
|
GB0519889D0
|
|
Lipopeptides as antitumoral compounds
|
|
GB0513516D0
|
|
New phenalenones as antitumoral compounds
|
|
GB0425829D0
|
|
Antitumoral compounds
|
|
GB0421990D0
|
|
Lipopeptides as antitumoral compounds
|
|
US2006014776A1
|
|
Antitumoral compounds
|
|
GB0327279D0
|
|
Antitumoral compounds
|
|
AU2003249078A1
|
|
New cytotoxic cyclopeptide and its use for the treatment of cancer
|
|
GB0317128D0
|
|
Use of antitumoral compounds
|
|
GB0314726D0
|
|
New cytotoxic depsipeptides
|
|
AU2003204339B2
|
|
Cytotoxic Alkaloid Derivatives Including Asmarine A and B Isolated from a Sponge
|
|
WO03033523A2
|
|
Cytotoxic compounds
|
|
GB0221696D0
|
|
IB-01212, a new cytotoxic cyclopeptide
|
